The primary objective of this study is to evaluate real-life persistence on lenacapavir (LEN) pre-exposure prophylaxis (PrEP) at W52 in diverse clinical settings in the US.

This is a non-interventional study where information is being gathered about how individuals decide if and when to use pre-exposure prophylaxis for HIV prevention over a 2-year period, and when they do, how consistently individuals use pre-exposure prophylaxis and specific kinds of pre-exposure prophylaxis, like lenacapavir. Participants must be at least 18 years or older and willing and able to comply with all study requirements.